Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AVI BioPharma's cancer vaccine enters phase III development

Dec. 27, 1999

DSMB recommends continuation of Allovectin-7 trials

Dec. 23, 1999

CeaVac trial reaches accrual goal; phase II trial will be expanded to phase III

Dec. 23, 1999

Transgene presents phase II data for cancer vaccine

Dec. 23, 1999

StressGen's new treatment for cervical dysplasia successfully completes phase I study

Dec. 14, 1999

Cell Genesys receives payment from Japan Tobacco for cancer vaccine milestone

Dec. 14, 1999

KRN-7000-stimulated human cells effective in vitro against melanoma cell lines

Dec. 13, 1999

ImmunoGen's lead tumor-activated prodrug enters the clinic

Dec. 13, 1999

LifeTime receives FDA clearance to begin phase I/II trials of anticancer drug

Dec. 10, 1999

Avax Technologies and Neptunus execute joint venture agreement

Dec. 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...